Company / Return on Assets (ROA)
Edgewise Therapeutics, Inc. Return on Assets (ROA) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-30.4%
FY2025
5-year range
-30.4% / -15.0%
FY2021-FY2025
Trend
-10.4%
vs FY2024
Sector context
#132 of 213
Health Care
What the data says
At -30.4%, Edgewise Therapeutics, Inc.'s return on assets (roa) ranks #132 of 213 in the Health Care sector. Declined from -29.5% to -30.4% over the past 2 years.
Based on SEC 10-K filings.
-30.4% in FY2025 with a 5-year CAGR of -17.3%.
Declined from -29.5% to -30.4% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -11.9pp
- 5-Year Change
- -17.3pp
- 10-Year Change
- -
Sector benchmark
#132 of 213 in Health CareTop 62% of 213This company -30.4% Sector average -24.2%
▼
-25.6% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 10.4% year-over-year.
- Currently 6.2pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -30.4% | -10.4% |
| FY2024 | -27.5% | +6.7% |
| FY2023 | -29.5% | -59.8% |
| FY2022 | -18.4% | -22.8% |
| FY2021 | -15.0% | -14.9% |
| FY2020 | -13.1% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026